Cancer Type: Leukemia, Myeloma, and Hematologic

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email [email protected].

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.

 

Switch to Advanced Search

202507085

202507173

202509187

202511028

Brief Summary The outcomes in patients with relapsed multiple myeloma refractory to triple-therapy (anti-CD38, immunomodulatory drugs (IMiD) and proteasome inhibitors (PI)) remain poor. These patients are eligible for chimeric antigen receptor T-cells (CAR-T), which rely on redirecting autologous T-cells to clear myeloma cells by targeting B-cell maturation antigen (BCMA). BCMA CAR-T therapy is not curative, and unlike autologous stem cell transplant, there is currently no standard for maintenance therapy post CAR-T which could potentially increase MRD rates and extend progression-free survival.

202511092

202601203

202603056

202603106

202604077